Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial

Ildiko Lingvay (Lead / Corresponding author), Andrei-Mircea Catarig, Juan P. Frias, Harish Kumar, Nanna L. Lausvig, Carel W. le Roux, Desirée Thielke, Adie Viljoen, Rory McCrimmon

Research output: Contribution to journal › Article › peer-review